Dr Noor Habboosh, MD | |
111 E 210th St, Bronx, NY 10467-2401 | |
(718) 920-4800 | |
Not Available |
Full Name | Dr Noor Habboosh |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 111 E 210th St, Bronx, New York |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1710564232 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 325608 (New York) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Noor Habboosh, MD 111 E 210th St, Bronx, NY 10467-2401 Ph: () - | Dr Noor Habboosh, MD 111 E 210th St, Bronx, NY 10467-2401 Ph: (718) 920-4800 |
News Archive
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced today that on September 4, 2009 it received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market (the "Staff") notifying the Company that it did not comply with the minimum $2,500,000 stockholders' equity requirement for continued listing, set forth in Listing Rule 5550(b), prior to the expiration of the extension for such compliance granted by the Staff on June 25, 2009, and that as a result, unless the Company requests an appeal of the Staff's delisting determination, trading of the Company's common stock on the Nasdaq Capital Market will be suspended at the opening of business on September 15, 2009.
Valeant Pharmaceuticals announced that it has introduced Kinerase(R) Intensive Eye Cream, based on the successful formula of its Kinerase facial lotion and cream. The new eye cream contains a 25 percent higher concentration of Kinetin, the natural substance in Kinerase products that helps the skin retain moisture and reduces the appearance of fine lines and wrinkles.
A biophotonic workshop hosted by the European Commission is set to examine the latest developments in clinical diagnostics.
Retractable Technologies, Inc. ("Retractable") (AMEX: RVP), a leading maker of safety needle devices, announced today that a Tyler, Texas jury returned a verdict on Friday, December 18th in the litigation of Retractable Technologies, Inc. v. OMI (Occupational & Medical Innovations Limited, an Australian public company,) in favor of Retractable on all claims presented to the jury.
› Verified 9 days ago